vs
渤健（BIIB）与摩森康胜饮品公司（TAP）财务数据对比。点击上方公司名可切换其他公司
摩森康胜饮品公司的季度营收约是渤健的1.4倍（$3.1B vs $2.3B），摩森康胜饮品公司净利率更高（7.6% vs -2.1%，领先9.8%），摩森康胜饮品公司同比增速更快（-3.6% vs -7.1%），渤健自由现金流更多（$468.0M vs $357.8M），过去两年摩森康胜饮品公司的营收复合增速更高（1.2% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
摩森康胜饮品公司是一家美加合资的跨国饮料酿造企业，旗下拥有多款知名酒精及非酒精饮品产品线，业务覆盖全球多个国家和地区，目前在伊利诺伊州芝加哥与魁北克省蒙特利尔设有双总部。
BIIB vs TAP — 直观对比
营收规模更大
TAP
是对方的1.4倍
$2.3B
营收增速更快
TAP
高出3.5%
-7.1%
净利率更高
TAP
高出9.8%
-2.1%
自由现金流更多
BIIB
多$110.2M
$357.8M
两年增速更快
TAP
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $3.1B |
| 净利润 | $-48.9M | $238.3M |
| 毛利率 | 78.3% | 31.0% |
| 营业利润率 | -2.5% | 10.4% |
| 净利率 | -2.1% | 7.6% |
| 营收同比 | -7.1% | -3.6% |
| 净利润同比 | -118.3% | -17.2% |
| 每股收益（稀释后） | $-0.35 | $1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBTAP
| Q4 25 | $2.3B | $3.1B | ||
| Q3 25 | $2.5B | $3.5B | ||
| Q2 25 | $2.6B | $3.7B | ||
| Q1 25 | $2.4B | $2.7B | ||
| Q4 24 | $2.5B | $3.2B | ||
| Q3 24 | $2.5B | $3.6B | ||
| Q2 24 | $2.5B | $3.8B | ||
| Q1 24 | $2.3B | $3.0B |
净利润BIIBTAP
| Q4 25 | $-48.9M | $238.3M | ||
| Q3 25 | $466.5M | $-2.9B | ||
| Q2 25 | $634.8M | $428.7M | ||
| Q1 25 | $240.5M | $121.0M | ||
| Q4 24 | $266.7M | $287.8M | ||
| Q3 24 | $388.5M | $199.8M | ||
| Q2 24 | $583.6M | $427.0M | ||
| Q1 24 | $393.4M | $207.8M |
毛利率BIIBTAP
| Q4 25 | 78.3% | 31.0% | ||
| Q3 25 | 73.4% | 33.7% | ||
| Q2 25 | 77.1% | 34.3% | ||
| Q1 25 | 74.1% | 31.6% | ||
| Q4 24 | 76.2% | 32.0% | ||
| Q3 24 | 74.1% | 33.4% | ||
| Q2 24 | 77.8% | 34.6% | ||
| Q1 24 | 76.3% | 31.6% |
营业利润率BIIBTAP
| Q4 25 | -2.5% | 10.4% | ||
| Q3 25 | 22.0% | -98.5% | ||
| Q2 25 | 28.1% | 15.6% | ||
| Q1 25 | 12.8% | 6.9% | ||
| Q4 24 | 11.9% | 12.0% | ||
| Q3 24 | 18.3% | 12.5% | ||
| Q2 24 | 28.3% | 15.6% | ||
| Q1 24 | 20.3% | 10.3% |
净利率BIIBTAP
| Q4 25 | -2.1% | 7.6% | ||
| Q3 25 | 18.4% | -84.0% | ||
| Q2 25 | 24.0% | 11.5% | ||
| Q1 25 | 9.9% | 4.5% | ||
| Q4 24 | 10.9% | 8.9% | ||
| Q3 24 | 15.8% | 5.5% | ||
| Q2 24 | 23.7% | 11.1% | ||
| Q1 24 | 17.2% | 6.8% |
每股收益（稀释后）BIIBTAP
| Q4 25 | $-0.35 | $1.32 | ||
| Q3 25 | $3.17 | $-14.79 | ||
| Q2 25 | $4.33 | $2.13 | ||
| Q1 25 | $1.64 | $0.59 | ||
| Q4 24 | $1.82 | $1.39 | ||
| Q3 24 | $2.66 | $0.96 | ||
| Q2 24 | $4.00 | $2.03 | ||
| Q1 24 | $2.70 | $0.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $896.5M |
| 总债务越低越好 | $6.3B | $6.3B |
| 股东权益账面价值 | $18.3B | $10.2B |
| 总资产 | $29.4B | $22.7B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.61× |
8季度趋势，按日历期对齐
现金及短期投资BIIBTAP
| Q4 25 | — | $896.5M | ||
| Q3 25 | — | $950.2M | ||
| Q2 25 | — | $613.8M | ||
| Q1 25 | — | $412.7M | ||
| Q4 24 | — | $969.3M | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $458.4M |
总债务BIIBTAP
| Q4 25 | $6.3B | $6.3B | ||
| Q3 25 | $6.3B | $6.3B | ||
| Q2 25 | $6.3B | $6.3B | ||
| Q1 25 | $4.5B | $6.2B | ||
| Q4 24 | $6.3B | $6.1B | ||
| Q3 24 | $4.5B | $6.2B | ||
| Q2 24 | $6.3B | $7.0B | ||
| Q1 24 | $6.3B | $6.2B |
股东权益BIIBTAP
| Q4 25 | $18.3B | $10.2B | ||
| Q3 25 | $18.2B | $10.3B | ||
| Q2 25 | $17.6B | $13.4B | ||
| Q1 25 | $17.0B | $13.1B | ||
| Q4 24 | $16.7B | $13.1B | ||
| Q3 24 | $16.4B | $13.3B | ||
| Q2 24 | $15.9B | $13.2B | ||
| Q1 24 | $15.2B | $13.1B |
总资产BIIBTAP
| Q4 25 | $29.4B | $22.7B | ||
| Q3 25 | $29.2B | $22.9B | ||
| Q2 25 | $28.3B | $26.8B | ||
| Q1 25 | $28.0B | $25.9B | ||
| Q4 24 | $28.0B | $26.1B | ||
| Q3 24 | $28.3B | $26.6B | ||
| Q2 24 | $26.8B | $27.4B | ||
| Q1 24 | $26.6B | $26.1B |
负债/权益比BIIBTAP
| Q4 25 | 0.34× | 0.61× | ||
| Q3 25 | 0.35× | 0.61× | ||
| Q2 25 | 0.36× | 0.47× | ||
| Q1 25 | 0.27× | 0.47× | ||
| Q4 24 | 0.38× | 0.47× | ||
| Q3 24 | 0.28× | 0.47× | ||
| Q2 24 | 0.40× | 0.53× | ||
| Q1 24 | 0.41× | 0.47× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $540.7M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $357.8M |
| 自由现金流率自由现金流/营收 | 20.5% | 11.4% |
| 资本支出强度资本支出/营收 | 1.9% | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.27× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $1.1B |
8季度趋势，按日历期对齐
经营现金流BIIBTAP
| Q4 25 | $511.9M | $540.7M | ||
| Q3 25 | $1.3B | $616.1M | ||
| Q2 25 | $160.9M | $718.3M | ||
| Q1 25 | $259.3M | $-90.7M | ||
| Q4 24 | $760.9M | $494.5M | ||
| Q3 24 | $935.6M | $521.2M | ||
| Q2 24 | $625.8M | $869.2M | ||
| Q1 24 | $553.2M | $25.4M |
自由现金流BIIBTAP
| Q4 25 | $468.0M | $357.8M | ||
| Q3 25 | $1.2B | $483.0M | ||
| Q2 25 | $134.3M | $555.0M | ||
| Q1 25 | $222.2M | $-328.0M | ||
| Q4 24 | $721.6M | $383.4M | ||
| Q3 24 | $900.6M | $350.4M | ||
| Q2 24 | $592.3M | $691.7M | ||
| Q1 24 | $507.3M | $-189.3M |
自由现金流率BIIBTAP
| Q4 25 | 20.5% | 11.4% | ||
| Q3 25 | 48.4% | 13.9% | ||
| Q2 25 | 5.1% | 14.8% | ||
| Q1 25 | 9.1% | -12.2% | ||
| Q4 24 | 29.4% | 11.8% | ||
| Q3 24 | 36.5% | 9.7% | ||
| Q2 24 | 24.0% | 18.0% | ||
| Q1 24 | 22.1% | -6.2% |
资本支出强度BIIBTAP
| Q4 25 | 1.9% | 5.9% | ||
| Q3 25 | 1.8% | 3.8% | ||
| Q2 25 | 1.0% | 4.4% | ||
| Q1 25 | 1.5% | 8.8% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 1.4% | 4.7% | ||
| Q2 24 | 1.4% | 4.6% | ||
| Q1 24 | 2.0% | 7.0% |
现金转化率BIIBTAP
| Q4 25 | — | 2.27× | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | 1.68× | ||
| Q1 25 | 1.08× | -0.75× | ||
| Q4 24 | 2.85× | 1.72× | ||
| Q3 24 | 2.41× | 2.61× | ||
| Q2 24 | 1.07× | 2.04× | ||
| Q1 24 | 1.41× | 0.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
TAP
暂无分部数据
